ReviewTherapeutic advances in drug safety2019
Postmarket surveillance: a review on key aspects and measures on the effective functioning in the context of the United Kingdom and Canada.
Review in Therapeutic advances in drug safety, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Pathogenesis-Driven Drug Repurposing with a Self-Nanoemulsifying Delivery System for Parkinson's Disease.Pharmaceuticals (Basel, Switzerland) · 2026Review
- After the green light: Evaluating drugs in Phase IV studies.Indian journal of pharmacology · 2026Review
- Safety of Intravenous Edaravone in Clinical Practice.Muscle & nerve · 2026Article
- Causal knowledge graph analysis identifies adverse drug effects.Bioinformatics (Oxford, England) · 2026Article
- Autonomous reporting of 'normal' chest X-rays by artificial intelligence in the United Kingdom; can we take the human out of the loop?BJR artificial intelligence · 2026Review
- Real-world data on aortic endografts: Gore Together aortic registry protocol.Frontiers in cardiovascular medicine · 2026Article
- Behavioral Responses to Healthcare Funding Decisions and Their Impact on Value for Money: Evidence From Australia.Health economics · 2025Article
- Impact of Regulatory Post-Market Safety Advisories on Prescribing Practices: An Interrupted Time Series Analysis.Clinical pharmacology and therapeutics · 2025Article
- Drug repurposing for Alzheimer's disease and other neurodegenerative disorders.Nature communications · 2025Review
- A Review of the Applications, Benefits, and Challenges of Generative AI for Sustainable Toxicology.Current research in toxicology · 2025Review
- Discrepancies in regulations in post-marketing safety surveillance of drug-device combination products in the EU and US: a review.Frontiers in drug safety and regulation · 2025Review
- Mitophagy and cGAS-STING crosstalk in neuroinflammation.Acta pharmaceutica Sinica. B · 2024Review
- Bridging the gap from medical to psychological safety assessment: consensus study in a digital mental health context.BJPsych open · 2024Article
- Characterizing and Comparing Adverse Drug Events Documented in 2 Spontaneous Reporting Systems in the Lower Mainland of British Columbia, Canada: Retrospective Observational Study.JMIR human factors · 2024Observational
- Editorial: Pharmacoepidemiology and pharmacovigilance post-marketing drug safety studies.Frontiers in pharmacology · 2024Article
- Evaluating the Potency of Selected Antibiotic Medications Dispensed in Community Pharmacies in Gwale, Kano, Nigeria.Antibiotics (Basel, Switzerland) · 2023Article
- Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea.Infectious diseases and therapy · 2023Article
- Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study.Therapeutic advances in drug safety · 2023Article
- Article
- Angiotensin II receptor blockers (ARBs) and manufacturing contamination: A retrospective National Register Study into suspected associated adverse drug reactions.British journal of clinical pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulatory approvals for the marketing of medicinal products authorize medical practitioners to prescribe drugs to a group of patients that are defined within the license of the medicinal product. However, such prescriptions are carried out in a controlled manner. Prior to being approved, the medicinal product will have been evaluated in a population pool containing fewer than 5,000 patients and in a predesigned environment where several factors may be lacking, such as the absence of women of childbearing potential, geriatric patients and paediatric patients. Therefore, it is not surprising that several major adverse drug reactions are detected only when the product has been prescribed to the general population. National and international regulatory bodies have devised systems for monitoring medicinal products after marketing, commonly known as postmarketing surveillance systems. Postmarketing surveillance refers to the process of monitoring the safety of drugs once they reach the market, after the successful completion of clinical trials. The primary purpose for conducting postmarketing surveillance is to identify previously unrecognized adverse effects as well as positive effects. The Yellow Card scheme, practiced in the United Kingdom and the Canada Vigilance Program adopted in the Canadian jurisdiction, are two of the most successful postmarketing surveillance systems implemented across the world. Therefore, this article intends to discuss postmarketing surveillance and its role in the context of the United Kingdom and Canadian jurisdictions with a view on presenting key aspects and measures that are employed for operating an efficient postmarketing surveillance system in regulated markets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.